"Hier gaat het om u. Dat is het gevoel dat wij u willen geven bij het IJsselland Ziekenhuis. Aan de telefoon, tijdens een consult en bij het bed. Of u nu patiënt bent of een naaste. Als u ons nodig heeft, dan zijn wij er. Onze mensen leveren daarvoor de best denkbare zorg. Professioneel en met aandacht. Elke dag en elk moment. Zorg die wij voortdurend vernieuwen en die wij elke dag beter proberen te maken. Als algemeen ziekenhuis zorgen wij in eerste instantie voor onze directe omgeving. Ons verzorgingsgebied strekt zich uit over Capelle aan den IJssel, Krimpen aan den IJssel, Nieuwerkerk aan den IJssel, Krimpenerwaard en (de oostelijke kant van) Rotterdam. Wij bieden een breed aanbod van medisch specialistische zorg. De Maag-, darm- en leve"

During the past decade, IJsselland ziekenhuis conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 2 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 2 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IJsselland ziekenhuis" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Erasmus Medical Center" with 2 trials sponsored, "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 2 trials sponsored, "3M" with 1 trials sponsored and "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IJsselland ziekenhuis" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 4 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Netherlands Heart Foundation" with 2 trials as a collaborator and "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 2 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "IJsselland ziekenhuis" are "Atherosclerotic Cardiovascular Disease" (2 trials), "Cardiovascular Diseases" (2 trials), "Hemorrhoids" (2 trials), "Hypercholesterolemia" (2 trials) and "Adjuvant Therapy" (1 trials). Many other conditions were trialed in "IJsselland ziekenhuis" in a lesser frequency.

Most popular intervention types in "IJsselland ziekenhuis" are "Drug" (13 trials), "Procedure" (4 trials), "Biological" (2 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "1 or 2 cycle(s) HDM (High Dose Melphalan)" (1 trials), "2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)" (1 trials), "Acetylsalicylic acid" (1 trials) and "Amoxicillin Clavulanate" (1 trials). Other intervention names were less common.

The vast majority of trials in "IJsselland ziekenhuis" are 25 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "IJsselland ziekenhuis". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in IJsselland ziekenhuis, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in IJsselland ziekenhuis, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".